North America RNA Based Therapeutic Market Size, Share & Industry Trends Analysis Report By Type (RNA Antisense and RNA Interference (RNAi)), By Application, By End User, By Country, Historical Data and Growth Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America RNA Based Therapeutic Market
Market Report Description
The North America RNA Based Therapeutic Market would witness market growth of 14.8% CAGR during the forecast period (2021-2027).
RNA polymerase synthesizes RNA from template DNA, with messenger RNA (mRNA) serving as a biomolecule that connects DNA expression and protein translation. Both coding and non-coding RNAs have drawn special attention in medicine due to their unique qualities (such as their typically single-stranded nature and their 2' OH group) as well as their propensity to adopt a variety of secondary/tertiary structures.
Antisense technology works by manufacturing a strand of RNA from a known gene sequence, whereas RNAi technology works by triggering the breakdown of specific mRNA molecules. These freshly formed RNA strands attach to mRNA, rendering it inactive. The ability of RNA-based therapies to silence genes is the key driver of market expansion.
North America is a lucrative hub for the RNA-based therapeutic market due to its robust and advanced healthcare infrastructure. North America is a region that comprises a significant number of patients that are being diagnosed with cancer. In addition, according to the data shared by the center for disease control and prevention, in 2019, there were 599,601 deaths that were caused by cancer of which 283,725 were among females while 315,876 were among males. The increasing prevalence of various chronic diseases among people across the region is also a crucial subject matter.
The US market dominated the North America RNA Based Therapeutic Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $3,959.7 million by 2027. The Canada market is estimated to witness a CAGR of 17.4% during (2021 - 2027). Additionally, The Mexico market would showcase a CAGR of 16.4% during (2021 - 2027).
Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.
Scope of the Study
Market Segments Covered in the Report:
- RNA Antisense
- RNA Interference (RNAi)
- Genetic disorders
- Auto immune disorders
By End User
- Research Institutes
- Hospitals & Clinics
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma, Inc.
- Alnylam Pharmaceuticals, Inc.
- Sanofi S.A. (Sanofi Genzyme)
- Biogen, Inc.
- Gradalis, Inc.
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Silence Therapeutics Plc
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free